Shengqiang Yu
Overview
Explore the profile of Shengqiang Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ding G, Wang T, Sun F, Liu M, Tang G, Yu S, et al.
NPJ Precis Oncol
. 2024 Nov;
8(1):256.
PMID: 39516330
The formation of human collagen requires the presence of Prolyl 3-hydroxylase 1 (P3H1), but the regulatory mechanism of P3H1 remained insufficiently understood. Our study aimed to identify the role of...
2.
Zheng W, Jiang W, Wu Q, Chen J, Zhang Z, Yu S, et al.
BMJ Open
. 2023 May;
13(4):e068044.
PMID: 37185648
Objectives: To compare the prognostic values of three lymph node staging systems in renal cell carcinoma (RCC), including the number of positive lymph nodes (NPLN), lymph node ratio (LNR) and...
3.
Liu W, Yu S
Kidney Dis (Basel)
. 2023 Feb;
9(1):12-25.
PMID: 36756081
Background: Mineralocorticoid receptor antagonists (MRAs) protect cardiorenal function by robust anti-inflammatory and antifibrotic functions beyond classical functions of maintaining fluid and electrolyte homeostasis. The application of traditional steroidal MRAs to...
4.
Dang L, Cao X, Zhang T, Sun Y, Tian S, Gong T, et al.
J Am Soc Nephrol
. 2022 Aug;
33(9):1708-1725.
PMID: 35918147
Background: Emerging evidence indicates that epigenetic modulation of gene expression plays a key role in the progression of autosomal dominant polycystic kidney disease (ADPKD). However, the molecular basis for how...
5.
Gong Y, Xie L, Yu S
Clin Interv Aging
. 2022 Jun;
17:915-923.
PMID: 35686029
Background: Older patients with chronic renal failure (CRF) which currently is referred to as end-stage renal disease (ESRD) are associated with higher mortality. In-center nocturnal dialysis (INHD) is a new...
6.
Bo X, Liu Y, Liao H, Bian R, Mei C, Yu S, et al.
Semin Dial
. 2021 Nov;
35(1):86-92.
PMID: 34845758
Hemodialysis is the most widely used renal replacement therapy for end-stage renal disease patients. Exhausted vascular access due to repeated indwelling central venous catheters is becoming a challenging clinical problem,...
7.
Xu D, Bian R, Tuo S, Li X, Chen J, Xing X, et al.
Clin Genet
. 2021 Jun;
100(3):340-347.
PMID: 34101167
PKD2 gene variants account for 4.5% to 20% of patients with autosomal dominant polycystic kidney disease (ADPKD). Little is known about the clinical characteristics of PKD2 variants in Chinese patients...
8.
Xue C, Yang B, Xu J, Zhou C, Zhang L, Gao X, et al.
Clin Kidney J
. 2021 Jun;
14(4):1042-1054.
PMID: 34094516
Background: The efficacy and safety of rituximab (RTX) in adult frequent-relapsing (FR) or steroid-dependent (SD) nephrotic syndrome (NS), including minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS), are still...
9.
Zheng W, Zhu W, Yu S, Li K, Ding Y, Wu Q, et al.
BMC Cancer
. 2020 Nov;
20(1):1066.
PMID: 33148204
Background: Heterogeneity of metastatic renal cell carcinoma (RCC) constraints accurate prognosis prediction of the tumor. We therefore aimed at developing a novel nomogram for accurate prediction of overall survival (OS)...
10.
Zhou H, Xie C, Li W, Zhan J, Chen W, Yang P, et al.
Int J Clin Exp Pathol
. 2020 Oct;
13(9):2415-2418.
PMID: 33042354
Epstein-Barr virus-positive follicular lymphoma (EBV-positive FL) is extremely uncommon, especially a histiocytoid morphology. Here we present a 70-year-old man who had EBV-positive FL with diffuse large B-cell lymphoma (DLBCL) transformation...